Trial Better: A Clinical Trials Podcast ERT

ERT’s Vice President of Trial Oversight, Chief Diversity Officer, and Trial Better podcast host, Otis Johnson, is joined by Jennifer Stacey, Senior Vice President of Clinical Science and Operations at TriNetX for a conversation on real world evidence. They discuss how the non-global nature of real world evidence is changing for the better, and what that means for clinical research going forward.

Otis Johnson, host of Trial Better, is joined by Dr. Eric Siemers, President of Siemers Integration, LLC and a Distinguished Medical Advisor at Cogstate. They explore the setbacks and progress in recent Alzheimer’s disease research, and why the industry has reason to be optimistic about breakthroughs in this field in the near future.

Host Otis Johnson sits down with Ken Getz, Founder and Chairman of CISCRP and a professor at the Tufts University School of Medicine. They discuss how the perception of clinical research has evolved during the COVID-19 pandemic, as well as what the industry can do to take advantage of this unique opportunity to improve its relationship with the public.

Trial Better host and ERT’s Vice President of Trial Oversight, Otis Johnson, is joined by Dan Brenner, founder and CEO of 1nHealth. They discuss the changing landscape of patient recruitment, and what sponsors should consider as they aim to develop digital recruitment strategies that reflect the patient voice and virtual platform.

Host Jason Eger is joined by Jim Kremidas, Executive Director of the Association of Clinical Research Professionals. They discuss trends in the clinical research workforce and why sponsors should be concerned about the future development pipeline, as well as changes the industry can make to better prepare individuals for successful clinical research careers.

Dr. Fabian Sandoval of the Emerson Clinical Research Institute shares his firsthand experiences and learnings on the topic of patient diversity in clinical research, including the importance of sharing both his successes and failures and important considerations for sites that want to improve the diversity of their patient populations.